We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 21, 2021

Atezolizumab + Bevacizumab and Chemotherapy in NSCLC Subgroups With EGFR Mutations or Liver or Brain Metastases

Journal of Thoracic Oncology


Additional Info

Journal of Thoracic Oncology
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
J Thorac Oncol 2021 Oct 06;[EPub Ahead of Print], N Nogami, F Barlesi, MA Socinski, M Reck, CA Thomas, F Cappuzzo, TSK Mok, G Finley, JG Aerts, F Orlandi, D Moro-Sibilot, RM Jotte, D Stroyakovskiy, LC Villaruz, D Rodríguez-Abreu, DW Lim, D Merritt, S Coleman, A Lee, G Shankar, W Yu, I Bara, M Nishio

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading